Ankylosing spondylitis (AS) is a frequent chronic inflammatory rheumatic disease that affects the axial skeleton, starting in the sacroiliac joints and spreading to the spine in most patients. Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for AS. Even if the use of anti-TNF agents has demonstrated good clinical efficacy in controlling inflammation, in contrast to other conditions such as rheumatoid arthritis and psoriatic arthritis, anti-TNF treatment has failed to demonstrate any benefit on the structural progression of AS, some data even suggesting that it may accelerate the formation of syndesmophytes that seems to be an independent process of TNF. Conversely, NSAIDs inhibit ossification phenomena independently of their anti-inflammatory properties, owing to a specific action on bone formation via prostaglandin inhibition. Several features suggest that a continuous NSAID therapy is needed, in addition to anti-TNF treatment, to prevent syndesmophyte formation in AS patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
188
continuous daily
on demand
Service de rhumatologie - CHU d'Amiens
Amiens, France
Service de rhumatologie - CHU de Besançon
Besançon, France
Service de Rhumatologie - CHU de Bordeaux
Bordeaux, France
service de rhumatologie - AP-HP - Hôpital Ambroise Paré
Boulogne-Billancourt, France
Service de rhumatologie - CHU de Brest
Brest, France
service de rhumatologie - CH de Cahors
Cahors, France
service de rhumatologie - CH Le Mans
Le Mans, France
service de rhumatologie - CHU de Limoges
Limoges, France
service de rhumatologie - CHU de Montpellier
Montpellier, France
service de rhumatologie - CHU de Nancy
Nancy, France
...and 12 more locations
Proportion of patients who show a significant radiographic progression between the two randomised groups of patients
Time frame: 24 month after the begin of the treatment
Radiologic evolution between-group comparison
This measure is a composite with : * MRI * Clinical evolution of patients * Quantitative analysis of mSASSS score
Time frame: At the inclusion (Day 0) and 24 month after after the inclusion (Day 0)(begin of the treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.